205 related articles for article (PubMed ID: 23183429)
41. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
42. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders.
Terrier B; Sène D; Saadoun D; Ghillani-Dalbin P; Thibault V; Delluc A; Piette JC; Cacoub P
Ann Rheum Dis; 2009 Jan; 68(1):89-93. PubMed ID: 18375535
[TBL] [Abstract][Full Text] [Related]
43. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.
Nasr SH; Valeri AM; Cornell LD; Fidler ME; Sethi S; D'Agati VD; Leung N
Clin J Am Soc Nephrol; 2012 Feb; 7(2):231-9. PubMed ID: 22156754
[TBL] [Abstract][Full Text] [Related]
44. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma.
Rossi D; Fangazio M; De Paoli L; Puma A; Riccomagno P; Pinto V; Zigrossi P; Ramponi A; Monga G; Gaidano G
Cancer; 2010 May; 116(9):2188-200. PubMed ID: 20198709
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
[TBL] [Abstract][Full Text] [Related]
46. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
[TBL] [Abstract][Full Text] [Related]
47. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins.
Bakshi NA; Gulbranson R; Garstka D; Bradwell AR; Keren DF
Am J Clin Pathol; 2005 Aug; 124(2):214-8. PubMed ID: 16040291
[TBL] [Abstract][Full Text] [Related]
48. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
49. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
Morra E; Cesana C; Klersy C; Barbarano L; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Miqueleiz S; Bernuzzi P; Nosari AM; Lazzarino M
Leukemia; 2004 Sep; 18(9):1512-7. PubMed ID: 15322559
[TBL] [Abstract][Full Text] [Related]
50. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F; Petrucci MT; Guffanti A; Marcheselli L; Rossi D; Callea V; Vincenzo F; De Muro M; Baraldi A; Villani O; Musto P; Bacigalupo A; Gaidano G; Avvisati G; Goldaniga M; Depaoli L; Baldini L
Clin Cancer Res; 2009 Jul; 15(13):4439-45. PubMed ID: 19509142
[TBL] [Abstract][Full Text] [Related]
51. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
52. Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma.
Al-Mulhim FA
Saudi Med J; 2005 Jan; 26(1):31-6. PubMed ID: 15756349
[TBL] [Abstract][Full Text] [Related]
53. Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings.
Baur A; Bartl R; Pellengahr C; Baltin V; Reiser M
Cancer; 2004 Dec; 101(11):2599-604. PubMed ID: 15503306
[TBL] [Abstract][Full Text] [Related]
54. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR; Brandhorst D; Sammet C; Kellert M; Daniels R; Schuett P; Poser M; Mueller S; Ebeling P; Welt A; Bradwell AR; Buttkereit U; Opalka B; Flasshove M; Moritz T; Seeber S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8706-14. PubMed ID: 16361557
[TBL] [Abstract][Full Text] [Related]
55. Magnetic resonance imaging of the spine in plasma cell dyscrasias. A review.
Pertuiset E; Bellaiche L; Lioté F; Laredo JD
Rev Rhum Engl Ed; 1996 Dec; 63(11):837-45. PubMed ID: 9010972
[TBL] [Abstract][Full Text] [Related]
56. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
57. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
[TBL] [Abstract][Full Text] [Related]
58. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
[TBL] [Abstract][Full Text] [Related]
59. Smoldering multiple myeloma.
Gao M; Yang G; Kong Y; Wu X; Shi J
Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
[TBL] [Abstract][Full Text] [Related]
60. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
Isola I; Moreno DF; Moga E; Mena MP; Tovar N; Rodríguez-Lobato LG; Oliver-Caldés A; Salgado MC; Brasó-Maristany F; Yagüe J; Cibeira MT; Prat A; Rosiñol L; Bladé J; Fernández de Larrea C
Ann Hematol; 2021 Dec; 100(12):2997-3005. PubMed ID: 34463804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
